BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/6/2016 9:19:00 AM | Browse: 1244 | Download: 1968
 |
Received |
|
2016-03-15 10:27 |
 |
Peer-Review Started |
|
2016-03-16 19:02 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2016-05-18 11:30 |
 |
Revised |
|
2016-05-23 20:24 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2016-06-02 08:28 |
 |
Second Decision by Editor-in-Chief |
|
2016-06-02 18:07 |
 |
Final Decision by Editorial Office Director |
|
2016-06-16 11:31 |
 |
Articles in Press |
|
2016-06-16 11:31 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-06-28 10:31 |
 |
Publish the Manuscript Online |
|
2016-07-06 09:19 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Sofosbuvir/velpatasvir: A promising combination
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Aldo Bonaventura and Fabrizio Montecucco |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fabrizio Montecucco, MD, PhD, Assistant Professor, First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, 6 viale Benedetto XV, 16132 Genoa, Italy. fabrizio.montecucco@unige.it |
| Key Words |
Hepatitis C virus; Sofosbuvir; Velpatasvir; NS5A inhibitor; NS5B inhibitor |
| Core Tip |
Hepatitis C virus (HCV) spread all over the world. In the last years, new therapies with direct anti-viral agents draw a great revolution thanks to several oral regimens combining different drugs of this class. The present editorial provides a brief overview on the association between two direct antiviral agents, sofo-zsbuvir and velpatasvir, and their implication in the treat-ment of HCV infection. |
| Publish Date |
2016-07-06 09:19 |
| Citation |
Bonaventura A, Montecucco F. Sofosbuvir/velpatasvir: A promising combination. World J Hepatol 2016; 8(19): 785-789 |
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i19/785.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i19.785 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.